ERBB2 and neoplasm: Although this satisfactory safety is mediated by de-targeting from endogenous ligand of HSV-1, the expression of human ERBB2 under the control of whey acidic protein (WAP) promoter63 does not fully recapitulate the orthotopic expression of the target and the potential on-target, off tumour-related toxicity.